Opening arguments have commenced in Illinois against Abbott Laboratories, as four mothers claim the company’s formula for premature babies led to necrotizing enterocolitis (NEC) in their infants. This trial is part of over 1,700 similar lawsuits nationwide. The plaintiffs argue Abbott failed to warn about the risks, while Abbott maintains no direct causation between its formula and NEC. The outcome could influence numerous pending cases and potentially impact Abbott’s product offerings for preterm infants. Abbott is appealing a $495m verdict from a previous Missouri trial, highlighting the ongoing legal challenges the company faces.
